Search - tctmd.com

Displaying 181 - 200 of 244

Sort: Relevancy | Date

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

News Daily News

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

Yael L. Maxwell

September 12, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

Lipid-Rich Plaque in Nonculprit Regions of the Target Vessel Predicts Future MACE Risk

Caitlin E. Cox

May 15, 2017

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

News Daily News

Updated AUC for Stable Ischemic Heart Disease Seek to Match ‘Appropriateness’ to Current Practice

Caitlin E. Cox

March 10, 2017

News Daily News

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Yael L. Maxwell

December 06, 2016

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Conference News ESC 2016

Prasugrel, Ticagrelor Give Similar Short-term Outcomes After Primary PCI: PRAGUE-18

Todd Neale

August 30, 2016

News Daily News

Beta-Blockers Not Beneficial After PCI for Stable Angina

Michael O'Riordan

August 17, 2016

News Daily News

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

L.A. McKeown

August 11, 2016

News Daily News

Statins Tied to Lower Mortality, Amputation Risks in PAD

Michael O'Riordan

May 09, 2016

News Daily News

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

Michael O'Riordan

April 14, 2016

News Conference News AHA 2015

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

Todd Neale

November 10, 2015

News Conference News AHA 2015

DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year

Yael L. Maxwell

November 09, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

Advertisement

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

ESC Updates Guidelines for Treating STEMI Patients

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Lipid-Rich Plaque in Nonculprit Regions of the Target Vessel Predicts Future MACE Risk

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Updated AUC for Stable Ischemic Heart Disease Seek to Match ‘Appropriateness’ to Current Practice

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Prasugrel, Ticagrelor Give Similar Short-term Outcomes After Primary PCI: PRAGUE-18

Beta-Blockers Not Beneficial After PCI for Stable Angina

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

Statins Tied to Lower Mortality, Amputation Risks in PAD

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year

Discussion Highlights Merits, Limitations of Small Trials

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content